Hemp and Parkinson’s Research: What We Know So Far

Last reviewed 10 December 2025

What Is Full-Spectrum Hemp?

Full-spectrum hemp is a type of hemp extract that contains the full range of naturally occurring compounds found in the hemp plant. These compounds include cannabinoids such as CBD (cannabidiol), CBDa (cannabidiolic acid), and legally permitted trace levels of THC (typically no more than 0.3% in the United States and similar limits in other regions). It also contains minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol), along with terpenes, which contribute aroma and may influence biological activity, and flavonoids, which are plant-based antioxidant compounds.

A central concept associated with full-spectrum hemp is the entourage effect. This term describes the idea that cannabinoids, terpenes, and other plant constituents may work together in ways that could influence their activity in the body differently than isolated compounds used individually. 

In addition to full-spectrum products, hemp extracts are also available as broad-spectrum and CBD isolates, each offering a different chemical profile. Broad-spectrum extracts still contain a variety of cannabinoids and terpenes, but they undergo further refinement to remove detectable levels of THC. In contrast, CBD isolate consists of only purified CBD, without any other cannabinoids, terpenes, or flavonoids.

Full-spectrum hemp retains the most complete representation of the hemp plant’s natural compounds, which is why it is often considered the most holistic form of extract. In recent years, interest in full-spectrum formulations has increased, particularly among individuals seeking plant-based approaches to support general well-being and balance. This growing attention also extends to communities affected by neurological conditions, including Parkinson’s disease, where some individuals are exploring full-spectrum hemp as part of their wellness routines.

While full-spectrum hemp is not a treatment and should not replace prescribed care, early research and user interest suggest it may hold potential worth further scientific investigation especially in areas related to sleep, stress response, inflammation pathways, and overall quality of life.

Understanding Parkinson’s Disease

Parkinson’s disease is a progressive neurological condition that primarily affects the brain regions responsible for movement, coordination, and motor control. The condition develops when dopamine-producing neurons in a part of the brain called the substantia nigra, within the basal ganglia, gradually degenerate. Dopamine plays a key role in transmitting signals that regulate smooth and controlled movement. As dopamine levels decline, communication between neural pathways becomes disrupted, leading to the characteristic symptoms associated with Parkinson’s.

The condition is most commonly recognized by its motor symptoms, which may include tremors at rest, muscle stiffness, slowed movement (bradykinesia), balance challenges, and changes in gait. In addition to these physical symptoms, many individuals also experience non-motor symptoms, such as sleep disturbances, fatigue, anxiety, mood changes, constipation, and cognitive changes. These non-motor aspects can be equally impactful and often appear before visible motor symptoms.

Current medical management typically focuses on symptom relief and supporting quality of life. Standard therapies may include medications such as levodopa, dopamine agonists, and in some cases, surgical approaches like deep brain stimulation. While these treatments can be effective in addressing certain symptoms, they do not stop or reverse the underlying neurodegenerative process.

Because Parkinson’s disease affects each person differently and treatment responses vary, some individuals and caregivers are exploring additional wellness strategies alongside standard care. This has contributed to increased interest in areas such as nutritional approaches, exercise therapy, stress management techniques, and plant-based wellness products, including full-spectrum hemp.

The Endocannabinoid System and Brain Health

The endocannabinoid system (ECS) is a complex biological signaling network that plays a central role in maintaining internal balance, or homeostasis, across various physiological systems. First identified in the 1990s during research on how cannabinoids interact with the body, the ECS has since been recognized as a regulator of multiple essential functions. These include mood regulation, sleep cycles, immune activity, pain perception, gastrointestinal function, and overall nervous system communication.

The ECS is made up of three key components:

• Endocannabinoids such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG), which are lipid-based neurotransmitters produced by the body as needed.
• Cannabinoid receptors, primarily CB1 and CB2, located throughout the brain, spinal cord, peripheral nerves, and immune tissues.
• Enzymes such as FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase), which break down endocannabinoids after they have carried out their signaling role.

Unlike traditional neurotransmitters, endocannabinoids are typically synthesized “on demand” rather than stored. This allows the ECS to act as a feedback system, adjusting communication between cells to help maintain stability when physiological pathways become overactive or underactive. For example, in the nervous system, the ECS can help regulate neuronal firing, reduce excessive excitatory activity, and support balanced signaling between brain regions involved in movement, memory, and emotional processing.

Emerging research indicates that the ECS may also influence neuroinflammation and oxidative stress, two factors widely studied in chronic neurological conditions. Studies have found that modulation of ECS pathways may affect how immune cells respond to stress and how neurons protect themselves from damage. This has led scientists to investigate whether cannabinoids either produced naturally by the body or introduced from external sources like full-spectrum hemp could influence these pathways.

Because cannabinoids from the hemp plant can interact with ECS receptors or influence ECS activity indirectly, researchers are exploring their potential role in brain health. This includes studying cannabinoids such as CBD, CBDa, CBGa, CBG and others to understand how they may affect pathways related to inflammation, oxidative stress, neural signaling, and quality-of-life measures. 

Relationship Between The ECS and Parkinson’s Disease

The relationship between the endocannabinoid system (ECS) and Parkinson’s disease (PD) has emerged as a significant area of scientific investigation. Research indicates that the ECS is active in key brain regions affected by Parkinson’s, including the basal ganglia, which play a central role in regulating movement. Alterations in endocannabinoid signaling and receptor expression have been observed in individuals with Parkinson’s, suggesting that the ECS may influence how the body responds to the disease and its progression.

Scientific studies, including the 2017 paper “Cannabinoids in Parkinson’s Disease”, highlighted the following relationship between the ECS and Parkinson’s Disaese;

• Receptor and signaling changes: Both CB1 and CB2 receptors, as well as broader endocannabinoid signaling pathways, are modified in PD-affected brain regions such as the basal ganglia. These changes point to a potential role of the ECS in motor dysfunction associated with Parkinson’s.
• Regulation of basal ganglia neurotransmission: ECS pathways interact with dopaminergic, glutamatergic, and GABAergic signaling. Since PD is characterized by the degeneration of dopamine-producing neurons, dysregulation of the ECS may contribute to variations in symptom severity and disease progression.

What the Research Says So Far

Preclinical Research (Cells and Animal Models) on cannabinoids and Parkinson’s Disease

1. Cannabinoids May Help Protect Dopamine-Producing Neurons

A 2024 systematic review examining phytocannabinoid use in animal models of Parkinson’s disease revealed cannabinoids could preserve dopaminergic neurons, which are the brain cells responsible for producing dopamine. Because Parkinson’s disease is characterized by the progressive loss of these cells, any compound that helps protect or preserve them may play a role in slowing the disease’s development. The review also reported that cannabinoids appeared to stabilize dopamine levels, which are crucial for smooth and coordinated movement. When dopamine levels decline, symptoms such as tremors, stiffness, and slowed movement become more pronounced. 

The review further highlighted improvements in movement-related behaviors across multiple animal studies. Subjects receiving cannabinoid interventions showed better motor coordination, fewer freezing episodes, and enhanced locomotion compared to controls. These improvements may be linked to the modulation of neurotransmitter activity within motor pathways, particularly within the basal ganglia, a brain region deeply affected by Parkinson’s. 

Another major takeaway from the review was the observed reduction in inflammation, oxidative stress, pain sensitivity, and stiffness (catalepsy). These factors are known drivers of symptom progression and neuronal damage in Parkinson’s disease. Inflammation and oxidative stress accelerate cell loss, while stiffness and pain affect quality of life and autonomy. 

2. Cannabinoids Influence the Movement-Control Centers of the Brain

A review article in 2022 summarized how cannabinoid signaling plays a regulatory role in the basal ganglia, the brain region responsible for coordination and motor function. These roles include: regulating the communication that is disrupted by the death of dopamine-producing cells, which is the primary cause of Parkinson’s disease. Specifically, the brain’s natural cannabinoid system acts as a crucial “dimmer switch” that fine-tunes signals between neurons. By activating its CB1 and CB2 receptors, it can help re-balance the imbalanced circuits and potentially offer neuroprotection to the remaining cells. 

In animal studies, cannabinoids such as WIN-55,212-2 reduced excitotoxicity (cell damage caused by overstimulation), glial activation (neuroinflammation), and oxidative stress, all key contributors to the breakdown of neurons in PD.

3. Cannabinoids May Improve Motor Function in Controlled Models

A 2022 meta-analysis, which combined the findings of 41 controlled animal studies, concluded that cannabinoids significantly improve motor function in preclinical models.  Motor symptoms, including tremors, muscle rigidity, slowness of movement, and impaired coordination are some of the most challenging aspects of Parkinson’s. Improvements in motor symptoms were measured using standard motor tests, such as the rotarod and pole tests, which assess balance, coordination, and grip strength in animals modeling Parkinson’s disease. 

4. CBD May Offer Neuroprotective and Symptom-Modulating Benefits

A 2025 study utilizing a standard Parkinson’s disease (PD) animal model, which employs a neurotoxin (6-OH-DA) to mimic the condition, investigated the therapeutic effects of repeated Cannabidiol (CBD) treatment. The research found that CBD offered comprehensive benefits by reducing the critical loss of dopamine-producing neurons and significantly lowering inflammation in the brain’s striatum. Critically, this protection at the cellular level translated into functional improvements, as the treated animals showed both enhanced motor function and a reduction in memory-related deficits, suggesting CBD has the potential to address both the motor and non-motor symptoms of PD.

Observational Studies and Surveys (Real-World Use and Patient Reports)

Human Observational Studies Suggest Potential Symptom Relief

A 2023 observational pilot study evaluating a combination of THC and CBD in individuals with Parkinson’s disease reported that several participants experienced perceived improvements in key symptoms, including pain, anxiety, and sleep disturbances. These symptoms are among the most difficult aspects of Parkinson’s to manage, especially as the disease progresses. While the study did not include a placebo-controlled design, the reported benefits indicate possible therapeutic relevance. However, some participants also experienced mild side effects such as drowsiness or difficulty concentrating, signaling the importance of personalized dosing and medical guidance.

A 2025 nationwide online survey in France, involving 1136 Parkinson’s disease (PD) patients, found that 5.9% used cannabis and 17.9% used CBD. Use of both substances was correlated with better knowledge of cannabinoids and a poor self-perceived household economic situation. For administration, cannabis was primarily ingested or smoked, while CBD was predominantly ingested (82.8%). Users reported that both cannabis and CBD were highly effective for managing sleep disorders, pain, and rigidity/cramps, leading to high levels of satisfaction. 

Safety and Considerations

While interest in cannabinoids continues to grow, safety remains an essential part of the conversation, particularly for individuals with Parkinson’s disease. Like any bioactive compound, full-spectrum hemp products may produce side effects. Some commonly reported effects include fatigue, dry mouth, changes in appetite, and mild gastrointestinal discomfort. These effects are generally considered manageable, but individual responses can vary, especially depending on dose, formulation, and product quality.

For those living with Parkinson’s disease, medical guidance is especially important. Cannabinoids may interact with certain medications, including levodopa or drugs metabolized through the same liver enzyme pathways. These interactions could alter how medication works in the body, potentially changing its effectiveness or increasing side effects. Consulting with a knowledgeable healthcare professional helps ensure safe integration, appropriate dosing strategies, and monitoring of treatment response over time.

It is also important to recognize that not everyone responds the same way to full-spectrum hemp. Factors such as metabolism, body weight, genetic variability, prior exposure to cannabinoids, and overall health can affect how a person reacts. Additionally, product potency, extraction method, and terpene profile may all influence effects. Because of this variability, many experts recommend starting with a low dose and gradually adjusting while tracking symptom changes and overall well-being. Quality testing, transparent labeling, and sourcing from reputable manufacturers are also key considerations for safety and consistency.

Choosing a Quality Full-Spectrum Hemp Product

When considering full-spectrum hemp, especially for neurological wellness, product quality is critical. Our Active Spectrum products are designed to meet the highest standards for consistency, safety, and efficacy including; 

• Third-party testing / Certificate of Analysis (COA): Every Active Spectrum product undergoes rigorous independent testing to verify cannabinoid content, potency, and purity, ensuring you know exactly what you are consuming.
• Organic cultivation: Our hemp is grown without synthetic pesticides or herbicides, supporting both plant integrity and consumer safety.
• Transparent extraction methods: Active Spectrum uses solvent-free, gentle extraction techniques that preserve the full range of cannabinoids, terpenes, and flavonoids, maintaining the plant’s natural entourage effect.
• Consistent cannabinoid profile: Each batch is carefully formulated for reliability, so users receive a predictable and uniform experience every time.

Quality is especially important in wellness and neurological applications, where precise cannabinoid ratios, purity, and bioavailability may influence symptom support, neuroprotective potential, and overall safety. 

FAQ on Hemp and Parkinson’s Disease

Is full-spectrum hemp the same as CBD oil?

No. Full-spectrum hemp contains a wide range of cannabinoids, including CBD, trace THC, terpenes, and flavonoids, whereas CBD oil may be an isolate (pure CBD) or broad-spectrum extract (CBD plus other compounds, but typically no THC). Full-spectrum products are thought to benefit from the “entourage effect,” where multiple plant compounds work together for enhanced effects.

How do researchers study cannabinoids for neurological health?

Scientists use a combination of approaches, including cellular models, animal studies, observational surveys, and controlled human trials. These studies help explore how cannabinoids affect neurotransmission, inflammation, oxidative stress, and other pathways involved in neurological conditions such as Parkinson’s disease.

Can full-spectrum hemp help manage Parkinson’s symptoms?

Emerging preclinical and observational evidence suggests cannabinoids may support motor and non-motor symptoms, including sleep, pain, anxiety, and rigidity. However, clinical research is still limited, and full-spectrum hemp should be considered a complementary wellness approach rather than a replacement for conventional treatments.

Are there side effects of using full-spectrum hemp?

Yes. Mild side effects can occur, such as fatigue, dry mouth, appetite changes, or mild cognitive effects. Individual responses vary based on metabolism, product potency, and overall health. Consulting a healthcare professional is recommended, especially for people taking Parkinson’s medications.

How do I choose a high-quality full-spectrum hemp product?

Look for products with third-party testing (COA), organic cultivation, transparent extraction procedures, and consistent cannabinoid profiles. Quality is especially important for neurological wellness, where purity and reliability may influence safety and potential benefits.

References:

1. Alonso-Alconada, D., Alvarez, F.J., Alvarez, A., Mielgo, V.E., Goñi-de-Cerio, F., Rey-Santano, M.C., Caballero, A., Martinez-Orgado, J. and Hilario, E. (2010). The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs. Brain Research, 1362, pp.150–159. https://doi.org/10.1016/j.brainres.2010.09.050
2. Amanda, Carolina, F., Cadena, P.G. and Valdemiro Amaro Silva-Jr (2024). Use of phytocanabinoids in animal models of parkinson’s disease: systematic review. NeuroToxicology, 105, pp.34–44. https://doi.org/10.1016/j.neuro.2024.08.002
3. Barré, T., Cazorla, G., Di Beo, V., Lopez, F., Radoszycki, L., Maradan, G., Baunez, C. and Carrieri, P. (2025). Patterns of Use and Patient-Reported Effects of Cannabinoids in People With PD: A Nationwide Survey. Parkinson’s disease, [online] 2025, p.2979089. https://doi.org/10.1155/padi/2979089
4. Berzenn Urbi, Lee, Y., Hughes, I., Thorning, S., Broadley, S., Sabet, A. and Saman Heshmat (2022). Effects of cannabinoids in Parkinson’s disease animal models: a systematic review and meta-analysis. BMJ open science, [online] 6(1). https://doi.org/10.1136/bmjos-2022-100302
5. BioSource Botanicals. (2024). Harnessing the Whole-Plant Advantage: Cannabis Extracts for Health and Prevention | BioSource Botanicals. [online] Available at: https://biosourcebotanicals.com/harnessing-the-whole-plant-advantage-cannabis-extracts-for-health-and-prevention/ [Accessed 9 Dec. 2025].
6. Echeverria-Villalobos, M., Todeschini, A.B., Stoicea, N., Fiorda-Diaz, J., Weaver, T. and Bergese, S.D. (2019). Perioperative care of cannabis users: A comprehensive review of pharmacological and anesthetic considerations. Journal of Clinical Anesthesia, 57, pp.41–49. https://doi.org/10.1016/j.jclinane.2019.03.011
7. Esfandi, A., Mehrafarin, A., Kalateh Jari, S., Naghdi Badi, H. and Larijani, K. (2025). Cannabidiol Extracted from Cannabis sativa L. Plant Shows Neuroprotective Impacts Against 6-HODA-Induced Neurotoxicity via Nrf2 Signal Transduction Pathway. Iranian journal of pharmaceutical research: IJPR, [online] 24(1), p.e160499. https://doi.org/10.5812/ijpr-160499
8. Hickey, J.P., Collins, A.E., Nelson, M.L., Chen, H. and Kalisch, B.E. (2024). Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer’s Disease. Current Issues in Molecular Biology, [online] 46(5), pp.4379–4402. https://doi.org/10.3390/cimb46050266
9. Latif, R. and Nawaz, T. (2025). Medicinal plants and human health: a comprehensive review of bioactive compounds, therapeutic effects, and applications. Phytochemistry Reviews. https://doi.org/10.1007/s11101-025-10194-7
10. Mayo Clinic (2024). Parkinson’s Disease. [online] Mayo Clinic. Available at: https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055
11. Skaper, S.D. and Di Marzo, V. (2012). Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philosophical Transactions of the Royal Society B: Biological Sciences, [online] 367(1607), pp.3193–3200. https://doi.org/10.1098/rstb.2012.0313
12. Sousa, A. and DiFrancisco-Donoghue, J. (2023). Cannabidiol and Tetrahydrocannabinol Use in Parkinson’s Disease: An Observational Pilot Study. Cureus. [online] https://doi.org/10.7759/cureus.42391
13. Stampanoni Bassi, M., Sancesario, A., Morace, R., Centonze, D. and Iezzi, E. (2017). Cannabinoids in Parkinson’s Disease. Cannabis and Cannabinoid Research, 2(1), pp.21–29. https://doi.org/10.1089/can.2017.0002
14. Wang, M., Liu, H. and Ma, Z. (2022). Roles of the Cannabinoid System in the Basal Ganglia in Parkinson’s Disease. Frontiers in Cellular Neuroscience, 16. https://doi.org/10.3389/fncel.2022.832854